CSL Plans Merger with Talecris
CSL and Talecris Biotherapeutics have signed a definitive merger agreement. Through this contract, CSL will acquire Talecris for a $3.1 billion sum, including a large sum of debt.
The combined organizations will own the most extensive plasma collection capabilities existing. This will support an adequate plasma supply used to manufacture an array of therapeutic products. As well, the combined organizations have the broadest array of therapies that are derived from plasma.
The acquisition of CSL will expand the research and development pipeline. The expanded infrastructure afforded by integrating the two will support improved efficiencies in manufacturing. Likewise, operating efficiencies will enable increased investment into research and development activities.
August 13, 2008 Related topics: Mergers & Acquisitions